Johnson & Johnson agreed to acquire Intra-Cellular Therapies, a company focused on treatments for central nervous system disorders, for about $14.6 billion. Katie Greifeld reports on “Bloomberg Open Interest.”
J&J to Buy Intra-Cellular for About $14 Billion
Estimated read time
1 min read
You May Also Like
More From Author
Max Emerson, Andres Camilo Split After Losing Home in L.A. Fires
January 14, 2025
World rival Humanity launches foundation to advance digital identity
January 14, 2025
+ There are no comments
Add yours